Robust multiplexing platform allows scientific team to secure FDA approval for diagnostic test
Here at Luminex, we are inspired by the remarkable work of our Licensed Technologies partners to improve healthcare, and we are humbled that they’ve chosen xMAP® Technology as the basis for their tests, services, and other needs.
Consider just one example: Grifols, a leading global healthcare company headquartered in Barcelona. Founded in 1909 as a pioneer in the plasma industry, Grifols makes a difference in people’s lives by developing plasma-derived medicines and other biopharmaceutical solutions. Millions with chronic or rare conditions can enjoy an improved quality of life thanks to the Grifols team.
Scientists choose xMAP Technology for its flexibility and multiplexing capabilities
Grifols employs more than 27,000 people in more than 30 countries. The company offers plasma-related products for transfusion medicine, as well as for life science research, clinical trials, and pharmaceutical and diagnostic manufacturing.
Scientists at Grifols chose xMAP for its flexibility and multiplexing capabilities, as they used it for complexity testing to evaluate 37 antigens in 11 different blood group systems. Greg Denomme, lab director at Grifols Laboratory Solutions, notes that the technology’s robustness made it possible for his team to secure FDA approval for their in vitro diagnostic test. “I personally have looked at other technologies and find that the xMAP had the fastest pathway to FDA licensing,” he says.
We were so impressed by what the Grifols team is doing that we sat down with Denomme and Kevin Jaglinski, commercial director for Grifols Laboratory Solutions, to create a short video with more details about their work. Enjoy!